Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients With Relapsed or Refractory B Cell Malignancies

Trial Profile

Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients With Relapsed or Refractory B Cell Malignancies

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Jan 2015

At a glance

  • Drugs SNS 01 (Primary)
  • Indications Diffuse large B cell lymphoma; Mantle-cell lymphoma; Multiple myeloma; Plasma cell leukaemia
  • Focus Adverse reactions
  • Sponsors Sevion Therapeutics
  • Most Recent Events

    • 10 Sep 2014 Planned primary completion date changed from 1 Aug 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov.
    • 29 Aug 2014 Results published in the Media Release.
    • 29 Aug 2014 Status changed from recruiting to active, no longer recruiting, as reported in a Senesco media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top